Recruiting

Testing a new HIV treatment approach in people on current therapy

Plain-English translation of NCT07596888 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated September 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is a Phase 1 trial testing a new medication called IAP086 in people living with HIV who are already on antiretroviral therapy (ART). Researchers want to understand how safe this medication is, how well people tolerate it, and how the body processes it. You would continue taking your regular HIV medications throughout the study.

Current HIV treatments work well for many people, but researchers are always looking for new options that might work better or offer different benefits. This medication is being studied to see if it could be a useful addition to HIV treatment approaches in the future.

Do you qualify?

You likely qualify if…

you are 18 to 70 years old
you have been diagnosed with HIV and can show documentation of your diagnosis
you have been on the same HIV medication regimen for at least 24 months
your viral load has been undetectable (below 50 copies) at your last two tests and at screening
your CD4 count is above 350 cells, showing your immune system is healthy enough
you are willing to continue your current HIV medications without any changes during the study

You likely don't qualify if…

you have hepatitis B or hepatitis C infection
you have blood counts that are too low (low platelets, white blood cells, or hemoglobin)
you have liver function problems shown by blood tests
you are enrolled in another study of an experimental drug
you cannot commit to study visits and follow-up for 28 days

What participation looks like

You would receive a single intravenous infusion of the study medication on Day 0. The study carefully staggers when participants receive the medication—each person is monitored closely for at least 24 hours after their infusion, and the next participant waits 6 days before receiving their dose. You would have check-ins and blood tests to monitor your safety and health over 28 days total, while continuing to take your regular HIV medications exactly as prescribed.

AI-generated summary from trial data · Sep 24, 2026 · Not medical advice

Testing a new HIV treatment approach in people on current therapy

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)